The American Society of Clinical Psychopharmacology (ASCP) annual meeting brings together leaders from academia, regulatory agencies, and industry to exchange insights on the ever-evolving landscape of CNS drug development. This year, ASCP convenes May 26-29 at the Loews Miami Beach Hotel in Miami, FL.
The CRC team is looking forward to attending and taking part in the conversations shaping the regulations, operations, and science behind innovative CNS therapies.
Since 2006, CRC has focused exclusively on delivering a better CRO experience for sponsors advancing CNS programs, building a team and a track record that partners can rely on. If you’ll be attending ASCP this May, CRC welcomes the opportunity to connect and explore how 20 years of bold CNS research can support your program.
MEET OUR ATTENDEES
Tom Zoda, Ph.D.
Dr. Zoda brings 30+ years of CNS clinical research experience across operations, business development, and executive leadership. He has overseen global, multi-center trials in schizophrenia, Alzheimer’s disease, insomnia, anxiety, multiple sclerosis, and epilepsy, and previously held leadership roles at Apex Innovative Sciences, CenExel, Syneos Health, and PPD.
Thomas Hochadel, Pharm.D.
Dr. Hochadel has 30+ years of experience across Phase I-IV clinical trials, including 75+ Phase I studies and 100+ later-phase trials in CNS indications such as Parkinson’s disease, Alzheimer’s disease, anxiety, ADHD, and schizophrenia. His work includes specialized pharmacology studies and leadership of multiple IND submissions.
Gary Kay, Ph.D.
Dr. Kay brings 35+ years of neuropsychology expertise, specializing in the effects of medications on cognition, mood, and psychomotor performance. A global leader in driving simulation research, he has led pivotal CNS trials and frequently advises federal agencies, including the U.S. Food and Drug Administration, and has testified before Congress.
Derry Green, Pharm.D., MSHS
Dr. Green has 10+ years of clinical trial experience and has spent the past 8 years at CRC leading multicenter studies across all phases. Her work spans indications including opioid use disorder, schizophrenia, ALS, migraine, OCD, trigeminal neuralgia, bipolar disorder, and acute pain.
Jason Casarella, MBA
Mr. Casarella brings nearly 30 years of drug development experience, advancing from Clinical Research Assistant to executive leadership. He has built and led high-performing commercial teams and established strong partnerships across small, midsize, and large organizations.
Jim Free
Mr. Free has 20+ years of experience building specialized site networks for complex indications, including agitation in dementia, Rett syndrome, anxiety, and treatment-resistant depression. He has led successful programs and supported multiple IND, NDA, and ANDA submissions.
SCHEDULE A CONVERSATION
Our team will be on site throughout ASCP and available to connect. Whether early in planning or actively navigating study execution, CRC welcomes the opportunity to discuss your program, share perspective, and explore how a focused CNS partner can support what comes next. Complete the form below to schedule time with the team.
